Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is highlighted as one of the most undervalued biotech stocks to buy now. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating with a $57.00 price target on August 6, based on strong growth outlook and financial performance.

In fiscal Q2 2025, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) exceeded expectations with an EPS of $3.28, surpassing estimates. The company reported $101.7 million in total revenue, driven by Tavalisse sales boosted by Medicare Part D changes.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotech company focused on developing targeted drugs in oncology and immunology, with products like Tavalisse and Fostamatinib in their portfolio. Despite potential, some suggest other AI stocks may offer better upside and lower risk.

For more insights on potential investments, check out reports on stocks that could double in 3 years and hidden AI stocks to buy now. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL), Sets a $57 PT